Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.
Defining and Understanding Adaptive Resistance in Cancer Immunotherapy.
复制标题
DOI：
10.1016/j.it.2018.05.001
复制
发表时间：
2018-08
影响因子：
16.8
通讯作者：
Chen L
中科院分区：
文献类型：
--
作者：
Kim TK;Herbst RS;Chen L
尽管抗程序性死亡(PD)(抗PD-1或抗B7-H1)疗法在晚期癌症患者中观察到了前所未有的肿瘤消退和长期生存益处，但很大一部分患者并未从这种治疗中受益，而且一小部分应答者复发。目前克服耐药性和提高抗PD治疗有效性的努力需要对耐药性有清楚的了解，并应优先于现有途径，使用随机组合和可用的治疗方案。在这里，我们将抗性分为三种类型，即靶标缺失抗性、原发抗性和获得性抗性。这种分类需要可靠、准确的组织采样，并根据微环境(TIME)中肿瘤免疫的四种分类对结果进行适当的解释。我们认为，对这些复杂的肿瘤-免疫相互作用以及这些类型真实耐药背后的细胞和分子机制的基本了解，是未来结合或超越抗PD治疗靶向正确靶点的关键。
Despite the unprecedented tumor regression and long-term survival benefit observed with anti-Programmed Death (PD) (anti-PD-1 or anti-B7-homolog 1 (B7-H1)) therapy in patients with advanced cancers, a large portion of patients do not benefit from such treatment and a fraction of responders relapse. Current efforts to overcome resistance and improve efficacy of anti-PD therapy require a clear understanding of resistance, and should precede current avenues using random combinations with available treatment regimens. Here, we categorized three types of resistance, namely target-missing, primary, and acquired resistance. This categorization requires reliable, accurate tissue sampling and appropriate interpretation of results based on the four classifications of tumor immunity in the microenvironment (TIME). We believe that fundamental understanding of these complex tumor-immune interactions and of the cellular and molecular mechanisms underlying these types of true resistance is the key for targeting the right targets in combination with or beyond anti-PD therapy in the future.
登录
查看更多内容
影响因子：
7.2
作者：
Lu, Chunwan;Redd, Priscilla S.;Liu, Kebin
通讯作者：
Liu, Kebin
影响因子：
64.5
作者：
Benci JL;Xu B;Qiu Y;Wu TJ;Dada H;Twyman-Saint Victor C;Cucolo L;Lee DSM;Pauken KE;Huang AC;Gangadhar TC;Amaravadi RK;Schuchter LM;Feldman MD;Ishwaran H;Vonderheide RH;Maity A;Wherry EJ;Minn AJ
通讯作者：
Minn AJ
T细胞共刺激和共抑制的分子机制。
DOI：
10.1038/nri3405
发表时间：
2013-04
期刊：
Nature reviews. Immunology
影响因子：
--
作者：
通讯作者：
--
影响因子：
16.6
作者：
Koyama S;Akbay EA;Li YY;Herter-Sprie GS;Buczkowski KA;Richards WG;Gandhi L;Redig AJ;Rodig SJ;Asahina H;Jones RE;Kulkarni MM;Kuraguchi M;Palakurthi S;Fecci PE;Johnson BE;Janne PA;Engelman JA;Gangadharan SP;Costa DB;Freeman GJ;Bueno R;Hodi FS;Dranoff G;Wong KK;Hammerman PS
通讯作者：
Hammerman PS
DOI：
10.1056/nejmoa1504030
发表时间：
2015-07-02
期刊：
The New England journal of medicine
影响因子：
--
作者：
Larkin J;Chiarion-Sileni V;Gonzalez R;Grob JJ;Cowey CL;Lao CD;Schadendorf D;Dummer R;Smylie M;Rutkowski P;Ferrucci PF;Hill A;Wagstaff J;Carlino MS;Haanen JB;Maio M;Marquez-Rodas I;McArthur GA;Ascierto PA;Long GV;Callahan MK;Postow MA;Grossmann K;Sznol M;Dreno B;Bastholt L;Yang A;Rollin LM;Horak C;Hodi FS;Wolchok JD
通讯作者：
Wolchok JD